Patents by Inventor Annika Kers
Annika Kers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8415483Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: GrantFiled: December 20, 2011Date of Patent: April 9, 2013Assignee: AstraZeneca ABInventors: Gabor Csjernyik, Sofia Karlström, Annika Kers, Karin Kolmodin, Martin Nylöf, Liselotte Öhberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Söderman, Britt-Marie Swahn, Stefan Von Berg
-
Publication number: 20120165347Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: December 20, 2011Publication date: June 28, 2012Applicant: ASTRAZENECA ABInventors: Gabor Csjernyik, Sofia Karlström, Annika Kers, Karin Kolmodin, Martin Nylöf, Liselotte Öhberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Söderman, Britt-Marie Swahn, Stefan Von Berg
-
Patent number: 8158785Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: GrantFiled: September 27, 2007Date of Patent: April 17, 2012Assignee: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlstrom, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Patent number: 7960395Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: GrantFiled: September 27, 2007Date of Patent: June 14, 2011Assignee: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlström, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20110105537Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: January 19, 2011Publication date: May 5, 2011Applicant: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlström, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20110059992Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: November 11, 2010Publication date: March 10, 2011Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LTD.Inventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jörg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Öhberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
-
Publication number: 20110021540Abstract: The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.Type: ApplicationFiled: November 14, 2008Publication date: January 27, 2011Applicant: ASTRAZENECA ABInventors: Johan Bylund, Maria Ek, Jorg Holenz, Martin H. Johansson, Annika Kers, Katja Narhi, Gunnar Nordvall, Liselotte Ohberg, Daniel Sohn, Jenny Viklund, Stefan Von Berg
-
Patent number: 7855213Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: GrantFiled: June 13, 2007Date of Patent: December 21, 2010Assignees: AstraZeneca AB, Astex Therapeutics Ltd.Inventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jörg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Öhberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
-
Publication number: 20100292279Abstract: The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.Type: ApplicationFiled: May 12, 2010Publication date: November 18, 2010Applicant: ASTRAZENECA ABInventors: Johan Bylund, Maria E. Ek, Jörg Holenz, Annika Kers, Liselotte Öhberg
-
Publication number: 20100035899Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: September 27, 2007Publication date: February 11, 2010Applicant: ASTRAZENECA ABInventors: Rolf Johansson, Sofia Karlstrom, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20090281138Abstract: The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.Type: ApplicationFiled: November 14, 2008Publication date: November 12, 2009Applicant: AstraZeneca ABInventors: Johan Bylund, Marie E. Ek, Annika Kers, Gunnar Nordvall, Liselotte Ohberg, Jenny Viklund, Stefan Von Berg, Jorg Holenz, Katja Narhi, Daniel Sohn, Martin H. Johansson
-
Patent number: 7585881Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.Type: GrantFiled: February 9, 2005Date of Patent: September 8, 2009Assignee: AstraZeneca ABInventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tau Xin, Jalaj Arora
-
Patent number: 7576077Abstract: The present invention is directed to compounds of formula I: wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, R3, R4, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.Type: GrantFiled: February 18, 2005Date of Patent: August 18, 2009Assignee: Astrazeneca ABInventors: David Wensbo, Martin Johansson, Alexander Minidis, Karin Staaf, Annika Kers, Louise Edwards, Methvin Isaac, Tom Stefanac, Abdelmalik Slassi, Don McLeod, Tao Xin
-
Publication number: 20090131468Abstract: The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.Type: ApplicationFiled: November 14, 2008Publication date: May 21, 2009Applicant: AstraZeneca ABInventors: Johan Bylund, Marie E. Ek, Annika Kers, Gunnar Nordvall, Liselotte Ohberg, Jenny Viklund, Stefan Von Berg, Jorg Holenz, Katja Narhi, Daniel Sohn, Martin H. Johansson
-
Publication number: 20080318981Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: September 27, 2007Publication date: December 25, 2008Applicant: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlstrom, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Patent number: 7456200Abstract: The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing compounds of the formula I and to the use of compounds of the formula I in therapy.Type: GrantFiled: November 14, 2005Date of Patent: November 25, 2008Assignee: Astrazeneca ABInventors: Jalaj Arora, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tomislav Stefanac, Thomas M. Stormann, David Wensbo, Tao Xin, Helena Gyback, Martin Johansson, Annika Kers, John Malmberg, Alexander Minidis, Karin Oscarsson, Mangus Waldman, Ulrika Yngve, Christoffer Osterwall
-
Publication number: 20080171771Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: June 13, 2007Publication date: July 17, 2008Applicants: AstraZeneca AB, Astex Therapeutics LtdInventors: James Arnold, Phil Edwards, Mark Sylvester, Stefan Berg, Jorg Holenz, Annika Kers, Karin Kolmodin, Laszlo Rakos, Liselotte Ohberg, Rotticci Didier, Gianni Chessari, Miles Congreve, Christopher Murray, Sahil Patel
-
Publication number: 20080045571Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.Type: ApplicationFiled: August 18, 2007Publication date: February 21, 2008Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
-
Publication number: 20080015204Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.Type: ApplicationFiled: August 18, 2007Publication date: January 17, 2008Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
-
Publication number: 20080015234Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.Type: ApplicationFiled: August 18, 2007Publication date: January 17, 2008Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora